Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19

N/ACompletedNCT04343404

University Hospital, Strasbourg, France100 enrolled

Overview

Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens to them.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Respiratory Distress Syndrome

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient over the age of 18; * Diagnostic COVID-19 by RT-PCR; * Hospitalisation in resuscitation for the management of complications related to COVID-19 * Implanted ECMO-VV during hospitalisation; * Patient agreeing to participate in the study Exclusion Criteria: * Sujet under guardianship or trusteeship * Sujet under safeguard of justice

Locations (1)

Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg

Strasbourg, France

Outcomes

Primary Outcomes

Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them

Time frame: Files analysed retrospectily from March 1st, 2020 to April 15, 2020 will be examined

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.